ClinicalTrials.gg
CompletedNCT01227707Updated Aug 17, 2015Results posted

A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.

A Phase 2 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 9 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-17.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Enrollment
149th of 224
43 · median 63
Started
2005
with 13 others
Phase 2
133 of 230
31 open now
Registered
95th of 230
by date
Lead sponsor
22 of 230
Hoffmann-La Roche

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 149th largest by enrollment of the 224 interventional ones that give a count, is one of 14 that started in 2005, is one of 133 in phase 2, and was the 95th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This open-label study will assess the efficacy and safety of Avastin (bevacizumab) plus Xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with locally advanced primary rectal cancer. Patients will receive 4 courses of Avastin at a dose of 5 mg/kg intravenously (iv) every 2 weeks and for 38 days Xeloda at dose of 825 mg/kg twice daily orally, plus radiation therapy. After surgery, adjuvant treatment with 5-fluorouracil/leucovorin and, at the discretion of the investigator, with Avastin 5 mg/kg iv every 2 weeks for at least 6 months will be given.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >=18 years of age
  • Patients with confirmed rectal cancer who are subject to surgery and would benefit from pre-operative combined chemo-radiotherapy
  • Measurable and/or evaluable lesions according to criteria
  • EOCG performance status 0-1

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy or chemotherapy for rectal cancer
  • Untreated or spinal cord compression or primary brain tumors
  • Chronic daily treatment with high-dose aspirin (>325 mg/day) or other medications known to predispose to gastrointestinal ulceration
  • Co-existing , or malignancies diagnosed within the last 5 years, with the exception of basal and squamous cell cancer, or cervical cancer in situ.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Single Arm

    Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda] · Radiation: Radiation therapy · Procedure: Mesorectal excision · Drug: 5-fluorouracil · Drug: leucovorin

Interventions

  • 5 mg/kg intravenously every 2 weeks, 4 cycles

  • 825 mg/m2 twice daily orally, 38 days

  • RadiationRadiation therapy

    Total dose of 45 Gy over 38 days

  • ProcedureMesorectal excision

    6-8 weeks after completion of neoadjuvant treatment

  • Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months

  • Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months

  • Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pathological Complete Response (pCR)

    pCR was defined as the absence of viable tumor cells, as determined by standard histologic procedure, in the tumor specimen (including regional lymph nodes) obtained at surgery. In order to minimize evaluation bias, tumor specimens were analyzed by both a central and local pathologist. The number of participants with pathological tumor stage 0 (pT0) and regional lymph nodes stage 0 (pN0) at surgery was determined. pCR was defined as the number of participants with pT0 and pN0 at surgery divided by the total number of participants with pathological tumor stage data collected.

    Time frame: 6 to 8 weeks following completion of neoadjuvant treatment

Secondary outcomes

  1. Percentage of Participants by Primary Tumor (T), Regional Lymph Nodes (N), and Distant Metastasis (M) Clinical Stage at Baseline and at the End of Neo-Adjuvant Treatment (NAT)

    The frequencies of clinical tumor stage T (0, 1, 2, 3, 4, or X), regional lymph nodes stage N (0, 1, 2, 3, or 4), and distant metastasis clinical stage M (0, 1, or X) at baseline and at the end of NAT were assessed. The frequencies of pathological tumor stage T and regional lymph nodes stage N at surgery were evaluated. The clinical tumor and lymph node status was assessed by clinical examination, endosonography, and/or rectosigmoidoscopy, and pelvic and abdomen computerized tomography (CT) scan or magnetic resonance imaging (MRI). Response to treatment had to be assessed within 6 weeks after end of treatment by using the same techniques performed at baseline.

    Time frame: Baseline (BL) and end of neoadjuvant treatment (within 6 weeks after the completion of study treatment)

  2. Percentage of Participants Undergoing Sphincter-Saving Surgery by Type of Procedure

    Time frame: 6 to 8 weeks after completion of study treatment

  3. Percentage of Participants With Complete Response (CR) at the End of Neoadjuvant Treatment

    Percentage of participants with CR was evaluated as the proportion of participants with complete response for the target and non-target lesions, separately, at the end of NAT according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions or all non-target lesions and normalization of tumor marker levels.

    Time frame: BL and within 6 weeks after the completion of study treatment

  4. Percentage of Participants With an Overall Response of CR at the End of Neoadjuvant Treatment

    Percentage of participants with an overall response of CR was evaluated as the proportion of participants with CR for the target and non-target lesions plus absence of new lesions at the end of NAT according to RECIST. CR was defined as disappearance of all target lesions, all non-target lesions, and normalization of tumor marker levels.

    Time frame: BL and within 6 weeks after the completion of study treatment

  5. Percentage of Participants With New Lesions at the Primary Tumor Site at the End of Neoadjuvant Treatment

    The percentage of participants with new lesions located at the primary tumor site were evaluated at the end of NAT.

    Time frame: BL and within 6 weeks after the completion of study treatment

  6. Percentage of Participants With Relapse During Follow-Up

    The percentage of participants with local and/or regional relapse during follow-up. New lesions located at rectum or at colon or at lymph node detected at the end of NAT were evaluated as local and/or regional relapse.

    Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months

  7. Disease-Free Survival (DFS) - Percentage of Participants With an Event

    DFS was defined as the time from treatment start date to the date of first progression of disease or date of death due to any cause.

    Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months

  8. DFS - Time to Event

    The time in months from date of start-of-treatment to the date of event defined as the first documented disease progression or death due to any cause. If a participant did not have an event, the time was censored at the date of last adequate tumor assessment. DFS was estimated using the Kaplan-Meier method.

    Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months

  9. Overall Survival (OS) - Percentage of Participants With an Event

    OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive.

    Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months

  10. OS - Time to Event

    OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive. OS was estimated using the Kaplan-Meier method.

    Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months

  11. Time to Disease Progression (TTP) - Percentage of Participants With an Event

    TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer.

    Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months

  12. TTP - Time to Event

    TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer. TTP was estimated using the Kaplan-Meier method.

    Time frame: BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months

07

Results

Posted Aug 15, 2014

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab (Bv)+Capecitabine/Bv+Leucovorin+5-fluorouracil
Started43
Completed19
Not completed24
Withdrew: Adverse event10
Withdrew: Progression of disease3
Withdrew: Withdrawal by subject1
Withdrew: Patient non-compliance3
Withdrew: Medical decision6
Withdrew: Death1

Outcome measures

PrimaryPercentage of Participants With Pathological Complete Response (pCR)

pCR was defined as the absence of viable tumor cells, as determined by standard histologic procedure, in the tumor specimen (including regional lymph nodes) obtained at surgery. In order to minimize evaluation bias, tumor specimens were analyzed by both a central and local pathologist. The number of participants with pathological tumor stage 0 (pT0) and regional lymph nodes stage 0 (pN0) at surgery was determined. pCR was defined as the number of participants with pT0 and pN0 at surgery divided by the total number of participants with pathological tumor stage data collected.

Time frame:
6 to 8 weeks following completion of neoadjuvant treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Pathological Complete Response (pCR)
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
Percentage of Participants With Pathological Complete Response (pCR)10.00 (2.79 to 23.66)
Statistical analysis
  • Bv+Capecitabine/Bv+Leucovorin+5-FU · one sample binomial test · p = 1.00
SecondaryPercentage of Participants by Primary Tumor (T), Regional Lymph Nodes (N), and Distant Metastasis (M) Clinical Stage at Baseline and at the End of Neo-Adjuvant Treatment (NAT)

The frequencies of clinical tumor stage T (0, 1, 2, 3, 4, or X), regional lymph nodes stage N (0, 1, 2, 3, or 4), and distant metastasis clinical stage M (0, 1, or X) at baseline and at the end of NAT were assessed. The frequencies of pathological tumor stage T and regional lymph nodes stage N at surgery were evaluated. The clinical tumor and lymph node status was assessed by clinical examination, endosonography, and/or rectosigmoidoscopy, and pelvic and abdomen computerized tomography (CT) scan or magnetic resonance imaging (MRI). Response to treatment had to be assessed within 6 weeks after end of treatment by using the same techniques performed at baseline.

Time frame:
Baseline (BL) and end of neoadjuvant treatment (within 6 weeks after the completion of study treatment)
Reported as:
Number · percentage of participants
Percentage of Participants by Primary Tumor (T), Regional Lymph Nodes (N), and Distant Metastasis (M) Clinical Stage at Baseline and at the End of Neo-Adjuvant Treatment (NAT)
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
Baseline: T0, N00
End of NAT: T0, N04.65
Baseline: T1, N00
End of NAT: T1, N04.65
Baseline: T1, NX0
End of NAT: T1, NX2.33
Baseline: T2, N00
End of NAT: T2, N018.60
Baseline: T2, N19.30
End of NAT: T2, N19.30
Baseline: T2, NX0
End of NAT: T2, NX6.98
Baseline: T3, N032.56
End of NAT: T3, N018.60
Baseline: T3, N146.51
End of NAT: T3, N19.30
Baseline: T3, N20
End of NAT: T3, N22.33
Baseline: T3, NX2.33
End of NAT: T3, NX6.98
Baseline: T4, N00
End of NAT: T4, N04.65
Baseline: T4, N12.33
End of NAT: T4, N10
Baseline: T4, N22.33
End of NAT: T4, N20
Baseline: T4, N32.33
End of NAT: T4, N30
Baseline: TX, N00
End of NAT: TX, N02.33
Baseline: TX, N22.33
End of NAT: TX, N20
Baseline: M097.67
End of NAT: M081.40
Baseline: M12.33
End of NAT: M12.33
Baseline: MX0
End of NAT: MX9.30
SecondaryPercentage of Participants Undergoing Sphincter-Saving Surgery by Type of Procedure
Time frame:
6 to 8 weeks after completion of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants Undergoing Sphincter-Saving Surgery by Type of Procedure
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
Anterior resection70.0
Abdomen-peritoneal amputation (Miles)22.5
Other3.0
Colostomy, temporary (n=32)47.50
Colostomy, definitive (n=32)32.50
No colostomy20.0
SecondaryPercentage of Participants With Complete Response (CR) at the End of Neoadjuvant Treatment

Percentage of participants with CR was evaluated as the proportion of participants with complete response for the target and non-target lesions, separately, at the end of NAT according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions or all non-target lesions and normalization of tumor marker levels.

Time frame:
BL and within 6 weeks after the completion of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) at the End of Neoadjuvant Treatment
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
CR of target lesion(s)11.63
CR of non-target lesion(s)18.60
SecondaryPercentage of Participants With an Overall Response of CR at the End of Neoadjuvant Treatment

Percentage of participants with an overall response of CR was evaluated as the proportion of participants with CR for the target and non-target lesions plus absence of new lesions at the end of NAT according to RECIST. CR was defined as disappearance of all target lesions, all non-target lesions, and normalization of tumor marker levels.

Time frame:
BL and within 6 weeks after the completion of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants With an Overall Response of CR at the End of Neoadjuvant Treatment
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
Percentage of Participants With an Overall Response of CR at the End of Neoadjuvant Treatment9.30
SecondaryPercentage of Participants With New Lesions at the Primary Tumor Site at the End of Neoadjuvant Treatment

The percentage of participants with new lesions located at the primary tumor site were evaluated at the end of NAT.

Time frame:
BL and within 6 weeks after the completion of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants With New Lesions at the Primary Tumor Site at the End of Neoadjuvant Treatment
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
Percentage of Participants With New Lesions at the Primary Tumor Site at the End of Neoadjuvant Treatment4.65
SecondaryPercentage of Participants With Relapse During Follow-Up

The percentage of participants with local and/or regional relapse during follow-up. New lesions located at rectum or at colon or at lymph node detected at the end of NAT were evaluated as local and/or regional relapse.

Time frame:
BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months
Reported as:
Number · percentage of participants
Percentage of Participants With Relapse During Follow-Up
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
No Relapse84.21
1 Relapse7.89
2 Relapses7.89
SecondaryDisease-Free Survival (DFS) - Percentage of Participants With an Event

DFS was defined as the time from treatment start date to the date of first progression of disease or date of death due to any cause.

Time frame:
BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months
Reported as:
Number · percentage of participants
Disease-Free Survival (DFS) - Percentage of Participants With an Event
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
Disease-Free Survival (DFS) - Percentage of Participants With an Event30.23
SecondaryDFS - Time to Event

The time in months from date of start-of-treatment to the date of event defined as the first documented disease progression or death due to any cause. If a participant did not have an event, the time was censored at the date of last adequate tumor assessment. DFS was estimated using the Kaplan-Meier method.

Time frame:
BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until progression, up to 45 months
Reported as:
Mean · months
DFS - Time to Event
monthsBv+Capecitabine/Bv+Leucovorin+5-FU
DFS - Time to Event27.43 ± 1.71
SecondaryOverall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive.

Time frame:
BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
Overall Survival (OS) - Percentage of Participants With an Event25.58
SecondaryOS - Time to Event

OS was defined as the time from the date of first day of treatment until death due to any cause or the last date the participant was known to be alive. OS was estimated using the Kaplan-Meier method.

Time frame:
BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months
Reported as:
Mean · months
OS - Time to Event
monthsBv+Capecitabine/Bv+Leucovorin+5-FU
OS - Time to Event32.14 ± 1.46
SecondaryTime to Disease Progression (TTP) - Percentage of Participants With an Event

TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer.

Time frame:
BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months
Reported as:
Number · percentage of participants
Time to Disease Progression (TTP) - Percentage of Participants With an Event
percentage of participantsBv+Capecitabine/Bv+Leucovorin+5-FU
Time to Disease Progression (TTP) - Percentage of Participants With an Event27.91
SecondaryTTP - Time to Event

TTP was defined as the time from date of treatment start until first documented progression of disease or death due to underlying cancer. TTP was estimated using the Kaplan-Meier method.

Time frame:
BL, within 6 weeks after the completion of neoadjuvant treatment, every 2 weeks for 1 year following surgery, every 3 months thereafter until death, up to 45 months
Reported as:
Mean · months
TTP - Time to Event
monthsBv+Capecitabine/Bv+Leucovorin+5-FU
TTP - Time to Event27.68 ± 1.72

Adverse events

Collected over Adverse events were collected from the date of first study-drug administration until 28 days after the last dose of study drug administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bv+Capecitabine/Bv+Leucovorin+5-FU—8/42 (19%)39/42 (92.9%)
Most frequent serious events
Most frequent serious events
EventBv+Capecitabine/Bv+Leucovorin+5-FU
DiarrhoeaGastrointestinal disorders1/42
Miocardic ischemiaCardiac disorders1/42
Bowel perforationGastrointestinal disorders1/42
Cardiac ischemiaCardiac disorders1/42
Anastomosis dehiscenceInjury, poisoning and procedural complications1/42
Intestinal occlusionGastrointestinal disorders1/42
Postoperative abscessInjury, poisoning and procedural complications1/42
IpokaliemiaMetabolism and nutrition disorders1/42
Most frequent other events
Showing 10 of 66
Most frequent other events
EventBv+Capecitabine/Bv+Leucovorin+5-FU
DiarrheaGastrointestinal disorders18/42
ProctalgiaGastrointestinal disorders10/42
NauseaGastrointestinal disorders9/42
HematocheziaGastrointestinal disorders8/42
LeukopeniaBlood and lymphatic system disorders7/42
Rectal tenesmusGastrointestinal disorders7/42
NeutropeniaBlood and lymphatic system disorders6/42
Abdominal painGastrointestinal disorders6/42
AstheniaGeneral disorders6/42
HypertensionVascular disorders6/42

Baseline characteristics

Intent to treat (ITT) population: all participants who were included in the trial by signing the informed consent and were assigned to a study patient number.

Age, Continuous
Age, Continuous(years)Bv+Capecitabine/Bv+Leucovorin+5-FU
Mean61.49 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)Bv+Capecitabine/Bv+Leucovorin+5-FU
Female18
Male25
08

Study locations

9 sites
  • Ancona, 60121, Italy
  • Bologna, 40139, Italy
  • Cuneo, 12100, Italy
  • Genova, 16132, Italy
  • Napoli, 80131, Italy
  • Paola, 87027, Italy
  • Pisa, 56100, Italy
  • Roma, 00135, Italy
  • Siena, 53100, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2010
First posted
Oct 25, 2010
Start
Nov 2005
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results first posted
Aug 15, 2014
Last update
Aug 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01227707
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 25, 2010
Start date
Nov 2005
Primary completion
Aug 2010
Completion
Aug 2010
Results posted
Aug 15, 2014
Last update
Aug 17, 2015

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Capecitabine · Fluorouracil · Leucovorin

Start the discussion